60% (range 45-64%), which was significantly higher than the allele burden of the entire JAK2 V617F-positive cohort (P ¼ 0.01).
Human erythroleukemia (HEL) is a rare heterogeneous entity representing 3-4% of acute myeloid leukemia (AML). 1 According to the World Health Organization (WHO), HEL is classified into three subgroups: (1) leukemia with multi-lineage dysplasia; (2) therapy-related AML and myelodysplastic syndromes and (3) acute erythroid leukemia subdivided in erythroleukemia (erythroid/myeloid) and pure erythroid leukemia. HEL affects preponderant males, and the age distribution of the disease appears to be bimodal, with a smaller peak below 20 years and a more definitive and broader peak in the seventh decade of life. 2 The oncogenesis of erythroleukemia in humans is not well known and may differ in the different subgroups. In animal models, erythroleukemia was recently proposed to evolve a multistep oncogenic process. 3 In transgenic mice, Spi-1/PU.1 hyperexpression induces the emergence of erythropoietin (Epo)-dependent proerythroblasts. This early blockage in erythroblast differentiation leads to anemia that can be treated by transfusion. However, in particular circumstances, growth-factorindependent malignant cells emerge leading to an acute leukemic phase. This oncogenic event is associated with the gain-of-function mutations in the Kit gene, conferring a constitutive receptor kinase activity and cell proliferation related to Erk1/2 and PI3K/Akt pathways activation. Nevertheless, this two-hit model of leukemogenesis has not been yet described in human erythroleukemia. We studied here the case of a 60-yearold male fulfilling the WHO classification criteria for erythroid leukemia (erythoblasts immunophenotyped as CD36 þ , GPA þ , c-Kit þ , GP41 À ) with multiple karyotype abnormalities. This patient showed a massive (over 60%) bone marrow proerythroblastic infiltration (Figure 1a) . In order to study the response of HEL blasts to the major erythroid growth factor, patient bone marrow aspirates were cultured in the presence or absence of Epo. The addition of Epo in culture medium allowed a long-term survival of blast cells (Figure 1b) . These data suggest that blasts were Epo-sensitive, and therefore specific of erythroid lineage. We also investigated whether the multistage leukemogenesis recently described could be valid in this case of HEL. We sought for the possible hyper-expression of PU.1 in these cells. However, reverse transcription-PCR for PU.1 was negative for this patient (Figure 1c) . These results suggest that in this case, high expression of spi-1/PU.1 is not involved in the arrest of proerythroblast differentiation as in the mouse model. GATA-1 has been shown to play a critical role in terminal erythroid differentiation, 4 and mutations in this gene have been linked to several human hematological disorders including X-linked dyserythropoietic anemia and thrombocytopenia, X-linked thrombocytopenia and beta-thalassemia, and Down's syndrome acute megakaryoblastic leukemia. However, sequencing of GATA-1 shows that this transcription factor was not mutated in this case of human erythroleukemia (not shown). In Spi-1/ PU.1 transgenic mouse, the second event (cell proliferating induction step) of leukemogenesis is the induction of constitutive activation of c-Kit due to mutations in codons 814 or 818. However, the most frequent activating mutations in human neoplasia (codons 560 and 816) were not mutated in this leukemia (Figure 1d and not shown) . Moreover, the complete sequence of the gene shows that c-Kit gene does not present any particular mutation of exon 8 as observed in some human neoplasia including AML and lymphoma (not shown). We also sequenced the Epo-R adaptor JAK2, since it was recently reported that JAK2 mutation (V617F) is present in most patients with polycythemia vera (PV), myelodysplasia (MSD) and essential thrombocytemia (ET) and some primary myelofibrosis. 5 However, this JAK2 mutation was not present in this patient. Altogether, our data suggest that this particular case of human erythroleukemia does not follow the two-hit model of leukemogenesis observed in transgenic mice. In humans, the only two-hit model described so far is the core binding factor AML 6 in which AML1/ETO or CBF/MYH11 translocation induces myeloid differentiation arrest, and c-Kit, Ras or FLT-3 mutations induce cell proliferation and inhibition of apoptosis. Therefore, further investigations in human erythroleukemia are needed to understand the leukemogenesis involved in this still incurable disease. 
